King's College London

Research portal

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus

Research output: Contribution to journalArticle

Standard

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. / Enocsson, Helena; Wirestam, Lina; Dahle, Charlotte; Padyukov, Leonid; Jönsen, Andreas; Urowitz, Murray B.; Gladman, Dafna D.; Romero-Diaz, Juanita; Bae, Sang Cheol; Fortin, Paul R.; Sanchez-Guerrero, Jorge; Clarke, Ann E.; Bernatsky, Sasha; Gordon, Caroline; Hanly, John G.; Wallace, Daniel J.; Isenberg, David A.; Rahman, Anisur; Merrill, Joan T.; Ginzler, Ellen; Alarcón, Graciela S.; Chatham, W. Winn; Petri, Michelle; Khamashta, Munther; Aranow, Cynthia; Mackay, Meggan; Dooley, Mary Anne; Manzi, Susan; Ramsey-Goldman, Rosalind; Nived, Ola; Steinsson, Kristjan; Zoma, Asad A.; Ruiz-Irastorza, Guillermo; Lim, S. Sam; Kalunian, Kenneth C.; Inanc, Murat; van Vollenhoven, Ronald F.; Ramos-Casals, Manuel; Kamen, Diane L.; Jacobsen, Søren; Peschken, Christine A.; Askanase, Anca; Stoll, Thomas; Bruce, Ian N.; Wetterö, Jonas; Sjöwall, Christopher.

In: Journal of Autoimmunity, Vol. 106, 102340, 01.2020.

Research output: Contribution to journalArticle

Harvard

Enocsson, H, Wirestam, L, Dahle, C, Padyukov, L, Jönsen, A, Urowitz, MB, Gladman, DD, Romero-Diaz, J, Bae, SC, Fortin, PR, Sanchez-Guerrero, J, Clarke, AE, Bernatsky, S, Gordon, C, Hanly, JG, Wallace, DJ, Isenberg, DA, Rahman, A, Merrill, JT, Ginzler, E, Alarcón, GS, Chatham, WW, Petri, M, Khamashta, M, Aranow, C, Mackay, M, Dooley, MA, Manzi, S, Ramsey-Goldman, R, Nived, O, Steinsson, K, Zoma, AA, Ruiz-Irastorza, G, Lim, SS, Kalunian, KC, Inanc, M, van Vollenhoven, RF, Ramos-Casals, M, Kamen, DL, Jacobsen, S, Peschken, CA, Askanase, A, Stoll, T, Bruce, IN, Wetterö, J & Sjöwall, C 2020, 'Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus', Journal of Autoimmunity, vol. 106, 102340. https://doi.org/10.1016/j.jaut.2019.102340

APA

Enocsson, H., Wirestam, L., Dahle, C., Padyukov, L., Jönsen, A., Urowitz, M. B., Gladman, D. D., Romero-Diaz, J., Bae, S. C., Fortin, P. R., Sanchez-Guerrero, J., Clarke, A. E., Bernatsky, S., Gordon, C., Hanly, J. G., Wallace, D. J., Isenberg, D. A., Rahman, A., Merrill, J. T., ... Sjöwall, C. (2020). Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 106, [102340]. https://doi.org/10.1016/j.jaut.2019.102340

Vancouver

Enocsson H, Wirestam L, Dahle C, Padyukov L, Jönsen A, Urowitz MB et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity. 2020 Jan;106. 102340. https://doi.org/10.1016/j.jaut.2019.102340

Author

Enocsson, Helena ; Wirestam, Lina ; Dahle, Charlotte ; Padyukov, Leonid ; Jönsen, Andreas ; Urowitz, Murray B. ; Gladman, Dafna D. ; Romero-Diaz, Juanita ; Bae, Sang Cheol ; Fortin, Paul R. ; Sanchez-Guerrero, Jorge ; Clarke, Ann E. ; Bernatsky, Sasha ; Gordon, Caroline ; Hanly, John G. ; Wallace, Daniel J. ; Isenberg, David A. ; Rahman, Anisur ; Merrill, Joan T. ; Ginzler, Ellen ; Alarcón, Graciela S. ; Chatham, W. Winn ; Petri, Michelle ; Khamashta, Munther ; Aranow, Cynthia ; Mackay, Meggan ; Dooley, Mary Anne ; Manzi, Susan ; Ramsey-Goldman, Rosalind ; Nived, Ola ; Steinsson, Kristjan ; Zoma, Asad A. ; Ruiz-Irastorza, Guillermo ; Lim, S. Sam ; Kalunian, Kenneth C. ; Inanc, Murat ; van Vollenhoven, Ronald F. ; Ramos-Casals, Manuel ; Kamen, Diane L. ; Jacobsen, Søren ; Peschken, Christine A. ; Askanase, Anca ; Stoll, Thomas ; Bruce, Ian N. ; Wetterö, Jonas ; Sjöwall, Christopher. / Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. In: Journal of Autoimmunity. 2020 ; Vol. 106.

Bibtex Download

@article{4ad123bd9fab49f7997f2a3ea03571ca,
title = "Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus",
abstract = "Objective: The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE. Methods: Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI). Results: The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03–1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007). Conclusion: Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.",
keywords = "Biomarker, Organ damage, Outcome, Prognosis, SLE",
author = "Helena Enocsson and Lina Wirestam and Charlotte Dahle and Leonid Padyukov and Andreas J{\"o}nsen and Urowitz, {Murray B.} and Gladman, {Dafna D.} and Juanita Romero-Diaz and Bae, {Sang Cheol} and Fortin, {Paul R.} and Jorge Sanchez-Guerrero and Clarke, {Ann E.} and Sasha Bernatsky and Caroline Gordon and Hanly, {John G.} and Wallace, {Daniel J.} and Isenberg, {David A.} and Anisur Rahman and Merrill, {Joan T.} and Ellen Ginzler and Alarc{\'o}n, {Graciela S.} and Chatham, {W. Winn} and Michelle Petri and Munther Khamashta and Cynthia Aranow and Meggan Mackay and Dooley, {Mary Anne} and Susan Manzi and Rosalind Ramsey-Goldman and Ola Nived and Kristjan Steinsson and Zoma, {Asad A.} and Guillermo Ruiz-Irastorza and Lim, {S. Sam} and Kalunian, {Kenneth C.} and Murat Inanc and {van Vollenhoven}, {Ronald F.} and Manuel Ramos-Casals and Kamen, {Diane L.} and S{\o}ren Jacobsen and Peschken, {Christine A.} and Anca Askanase and Thomas Stoll and Bruce, {Ian N.} and Jonas Wetter{\"o} and Christopher Sj{\"o}wall",
year = "2020",
month = jan,
doi = "10.1016/j.jaut.2019.102340",
language = "English",
volume = "106",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "ACADEMIC PRESS INC",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus

AU - Enocsson, Helena

AU - Wirestam, Lina

AU - Dahle, Charlotte

AU - Padyukov, Leonid

AU - Jönsen, Andreas

AU - Urowitz, Murray B.

AU - Gladman, Dafna D.

AU - Romero-Diaz, Juanita

AU - Bae, Sang Cheol

AU - Fortin, Paul R.

AU - Sanchez-Guerrero, Jorge

AU - Clarke, Ann E.

AU - Bernatsky, Sasha

AU - Gordon, Caroline

AU - Hanly, John G.

AU - Wallace, Daniel J.

AU - Isenberg, David A.

AU - Rahman, Anisur

AU - Merrill, Joan T.

AU - Ginzler, Ellen

AU - Alarcón, Graciela S.

AU - Chatham, W. Winn

AU - Petri, Michelle

AU - Khamashta, Munther

AU - Aranow, Cynthia

AU - Mackay, Meggan

AU - Dooley, Mary Anne

AU - Manzi, Susan

AU - Ramsey-Goldman, Rosalind

AU - Nived, Ola

AU - Steinsson, Kristjan

AU - Zoma, Asad A.

AU - Ruiz-Irastorza, Guillermo

AU - Lim, S. Sam

AU - Kalunian, Kenneth C.

AU - Inanc, Murat

AU - van Vollenhoven, Ronald F.

AU - Ramos-Casals, Manuel

AU - Kamen, Diane L.

AU - Jacobsen, Søren

AU - Peschken, Christine A.

AU - Askanase, Anca

AU - Stoll, Thomas

AU - Bruce, Ian N.

AU - Wetterö, Jonas

AU - Sjöwall, Christopher

PY - 2020/1

Y1 - 2020/1

N2 - Objective: The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE. Methods: Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI). Results: The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03–1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007). Conclusion: Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.

AB - Objective: The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE. Methods: Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI). Results: The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03–1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007). Conclusion: Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.

KW - Biomarker

KW - Organ damage

KW - Outcome

KW - Prognosis

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=85073722485&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2019.102340

DO - 10.1016/j.jaut.2019.102340

M3 - Article

C2 - 31629628

AN - SCOPUS:85073722485

VL - 106

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

M1 - 102340

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454